ANNOUNCEMENT TRANSMITTED BY BUSINESS WIRE. THE CONTENT IS THE SOLE RESPONSIBILITY OF THE REPORTING COMPANY.
SAN FRANCISCO --(BUSINESS WIRE)-- 11.11.2025 --
Blue Matter today announced the expansion of its TwineTM data platform's capabilities in response to accelerating demand from biopharma companies. Enhancements include thoughtful use of artificial intelligence (AI) for advanced analytics and narratives, expanded data source integrations, master data management, and broader deployment across oncology and specialty therapeutic areas.
TwineTM is Blue Matter's purpose-built customer intelligence platform for healthcare and life sciences companies. It transforms complex data from disparate sources including specialty pharmacy networks, hub services, claims databases, and other third party data sources into actionable insights that drive commercial strategy and operational excellence. With generative AI at its core, Twine helps companies more effectively acquire, master, validate, and analyze data from internal and third-party sources. Persona-specific outputs enable faster, more informed decision-making.
According to Deepak Gopinath, Partner at Blue Matter, "What started as a solution for managing complex oncology data has evolved into a comprehensive platform that's helping transform data into competitive advantage across multiple therapeutic areas. AI is thoughtfully woven into every aspect of the platform to support enhanced data integration, a natural language interface, and more. The response has been very encouraging."
Key enhancements include:
- Advanced Analytics with AI: Incorporating proactive data narratives and reasoning capabilities to understand the "why" in addition to the "what"
- Natural Language Interface: Enhanced natural language processing capabilities that allow users to query complex datasets using conversational interfaces in addition to standardized reports
- Expanded Data Integrations: Pre-built connectors for more data sources and emerging digital health platforms
- Enhanced Master Data Management: Sophisticated entity resolution and data stewardship workflows optimized for specialty pharmaceutical operations
- Industry-Specific Accelerators: Pre-configured data models and KPIs tailored for a range of specialty therapeutic areas
Blue Matter continues to invest in Twine's technology roadmap, with even more improvements in the works. "We're proud of what we've built," said Prasanna Sridharan, Managing Partner of Blue Matter Insights. "But in the spirit of continuous improvement, we're constantly evolving it to meet our clients' changing needs. This expansion enables us to serve more companies while maintaining the specialized focus that makes Twine unique."
About Blue Matter
Blue Matter (www.bluematterconsulting.com) is a strategic consulting firm serving the life sciences industry. From its offices in North America, Europe and Asia, Blue Matter serves pharmaceutical and biotech companies around the globe. The firm helps clients maximize value at the product, portfolio, and organization levels with a focus on corporate and product strategy in complex markets, as well as organizational effectiveness.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251111395877/en/
For more information, contact:
Craig Dunkley
cdunkley@bluematterconsulting.com
(919) 539-0658
